The Future of Biology: 2040 Perspectives

Introduction: Biology's Grand Transformation

Biology is undergoing the most profound transformation in its history—from a descriptive science cataloguing life's diversity to a precise engineering discipline capable of reading, writing, and reprogramming the molecular logic of living systems. The convergence of exponentially improving sequencing, synthesis, computing, AI, and genome editing technologies is enabling biological interventions of unprecedented precision and scope. By 2040, several converging capabilities are likely to reshape medicine, agriculture, materials science, and our understanding of what life itself is: reading and writing genomes at cost approaching zero, predicting protein structure and function computationally, designing new organisms and molecules with desired properties, and beginning to understand ageing as a modifiable biological programme.

The foundational discoveries of the first century of molecular biology—DNA structure, the genetic code, restriction enzymes, PCR, genome sequencing, gene expression regulation, CRISPR—provide the platform for 21st century biology's engineering phase. Programmatic themes for 2040 include: computation-biology convergence (AI predicting molecular biology), base-resolution genome programming (therapeutic genome editing at scale), biological complexity from bottom-up (synthetic cells and minimal genomes), precision medicine from multi-omic stratification (right patient, right treatment, right time), and the longevity biology revolution (extending healthy lifespan by targeting ageing mechanisms rather than individual diseases).

AI and Computational Biology

AI-Designed Proteins and Therapeutics

AlphaFold2 solved the protein structure prediction problem for single protein chains; AlphaFold3 and RoseTTAFold-All-Atom extend this to protein complexes with ligands, DNA, RNA, and post-translational modifications—enabling computational drug discovery starting from structure rather than phenotypic screens. The next step is protein design: generating novel amino acid sequences with desired structural and functional properties. RFdiffusion, ProteinMPNN, and ESMFold-based design generate de novo proteins (enzymes, binders, biomaterials) not found in nature with defined folds and binding specificity. In 2023, researchers using RFdiffusion designed luciferases, GFP variants, and de novo enzyme active sites—demonstrating AI-enabled biology discovery. By 2040, AI-designed antibodies, enzyme cascades, gene circuits, and therapeutic proteins may bypass classical drug discovery timelines from years to months.

Multimodal Biological AI

Foundation models for biology trained on sequences, structures, perturbations, single-cell transcriptomes, and clinical data simultaneously are learning the underlying grammar of molecular biology. Geneformer (BERT for single-cell transcriptomes), BioGPT (language model for biomedical text), and scGPT (single-cell foundation model) are early examples of biological foundation models enabling zero-shot prediction of gene functions, cell type identities, and perturbation effects. Virtual cell models—computational models predicting genome-wide transcriptional responses to any gene knockout, drug treatment, or genetic variant—are being trained on large-scale Perturb-seq datasets. By 2040, a virtual cell could enable in silico drug screening removing most failed preclinical experiments, personalised treatment selection operating from a patient's omics profile through a virtual patient model, and accelerated mechanistic hypothesis testing beyond experimental throughput.

Genome Programming and Gene Therapy

In Vivo Base and Prime Editing

The transition from CRISPR nuclease cuts to base editing (C→T and A→G transitions without breaks) and prime editing (any substitution, insertion, deletion up to ~200 bp without breaks) eliminates the dominant risks of CRISPR therapy—translocations from double-strand breaks and large deletions at cut sites. Systemic LNP delivery of base editors to hepatocytes is already demonstrating near-complete correction of transthyretin amyloidosis (ATTR) and familial hypercholesterolaemia in Phase I clinical trials (2023-2024). By 2040, base editing therapies may be approved for sickle cell disease, beta-thalassemia, multiple haematological conditions, and liver metabolic diseases—treating genetic conditions affecting hundreds of millions of patients who currently lack curative options. Advances in LNP tissue targeting chemistry will open extrahepatic delivery to lung, CNS, muscle, kidney, and perhaps every organ.

Longevity Biology

Ageing is increasingly understood as a biological programme—not inevitable entropy—subject to modification by targeting its molecular drivers: telomere attrition, mitochondrial dysfunction, epigenetic drift, chronic inflammation (inflammaging), disabled autophagy, senescent cell accumulation, stem cell exhaustion, and altered intercellular communication. Interventions extending healthy lifespan in model organisms (rapamycin, caloric restriction mimetics, senolytics, NAD+ precursors, GDF11, young plasma factors) provide proof-of-concept that the biology of ageing is tractable. The first drugs specifically approved for targeting ageing biology (senolytics for age-related diseases) will likely appear before 2030; by 2040, combinatorial interventions targeting multiple pillars of ageing may be standard geriatric medicine—not merely treating individual diseases but addressing the fundamental biology producing them simultaneously.

Examples and Applications

Example 1: Whole-Genome Preimplantation Sequencing

By 2040, IVF preimplantation testing will likely include comprehensive genome sequencing of embryos—not merely aneuploid detection but polygenic scoring for disease risk and potentially positive trait selection. Current PGT-A already selects euploid embryos improving IVF success rates; adding polygenic risk scores for common diseases (CAD, T2DM, schizophrenia, educational attainment) using genome-wide SNP profiles provides additional selection information. The profound ethical implications—who controls what traits are selected, the disability rights perspective on 'eliminating' various conditions, exacerbation of social inequalities through 'designer babies'—are as significant as the technical capabilities. Regulatory frameworks will be essential to ensure these capabilities are used ethically, equitably, and with appropriate consent. The biology enables this; whether society should allow it requires careful ongoing ethical deliberation.

Example 2: Brain-Computer Interface Biology

As neural interface technology improves from hundreds to millions of recording and stimulating sites with wireless transmission, chronic implantation stability, and AI decoding enabling high-bandwidth thought-to-action interfaces, the frontier of therapeutic restoration expands. Locked-in ALS patients restored to full communication; paralysed individuals walking through decoded motor cortex output driving functional electrical stimulation; cochlear implants with optical channels providing 1000-electrode temporal resolution approaching normal hearing; and eventually bidirectional interfaces feeding artificial sensations back to somatosensory cortex. The biology challenges include immune and foreign body reactions to chronic neural implants, neural tissue damage from recording array insertion, and the need for stable long-term recordings from the same neurons. Soft bioelectronics matching brain tissue mechanical properties, biodegradable transient interfaces, and injection-delivered mesh electronics are approaches addressing these challenges.

Example 3: Synthetic Cells and Minimal Genomes

The JCVI synthesis of Mycoplasma mycoides genome (2010), viable synthetic cell (JCVI Syn1.0), and design of minimal genome Syn3.0 (473 gene minimal self-replicating cell, 31% of genes with unknown function)—established that artificial construction of cellular life from chemistry is possible. Future synthetic cells will serve as living factories for biopharmaceutical production, environmental biosensors, biodegradable materials manufacturing, and perhaps therapeutic cells engineered entirely from standardised genetic parts. Bottom-up synthetic cell construction (assembling lipid vesicles with transcription-translation systems, metabolic modules, and minimal replication machinery without any natural cell starting material) would provide the ultimate test of our understanding of the minimal requirements for life—and enable creation of biology not existing in nature. Synthetic cell programmes at Delft, Cambridge, and JCVI are systematically approaching this goal.

Example 4: Programmable Microbiome Medicine

By 2040, the gut microbiome may be programmable—selectively adding, removing, or modifying microbial strains and communities to treat disease. Current FMT (faecal microbiome transplantation) achieved as high as 87% efficacy for recurrent C. difficile infection—a success pointing toward more refined and targeted microbiome interventions. Engineered bacteria (SYNB1891, Synlogic's engineered E. coli Nissle producing ammonia-capture enzymes for hyperammonemia) are in clinical trials for monogenic metabolic diseases. Anti-microbiome bacteriophage cocktails selectively eliminate specific pathogenic strains while sparing the microbiome. Cancer immunotherapy efficacy is partly determined by gut microbiome composition—microbiome modulation improving response rates to anti-PD-1 in melanoma patients has early clinical support from human studies. Precision microbiome diagnostics, strain-level resolution sequencing, and targeted modulation will transform management of IBD, obesity, allergy, CNS, and cardiovascular diseases linked to microbiome dysbiosis.

Example 5: Epigenetic Reprogramming for Rejuvenation

The discovery that transient expression of Yamanaka reprogramming factors (Oct4, Sox2, Klf4, c-Myc) partially reverses epigenetic age without full dedifferentiation to pluripotency in aged mice (Sinclair, Belmonte laboratories) opened the age reprogramming field. OSK (Oct4, Sox2, Klf4) factors expressed via AAV in aged retinal ganglion cells restored youthful epigenetic patterns and regenerated axons after crush injury—the first in vivo epigenetic rejuvenation showing functional recovery. Clinical programmes: Retinal restoration using AAV-OSK gene therapy for glaucoma (Life Biosciences, Sinclair Lab collaboration); systemic partial reprogramming using pulsed cyclic factor expression or small molecules triggering similar pathway activation. Defining the boundary between safe partial reprogramming (reversing epigenetic age) and dangerous dedifferentiation (pathway to cancer or teratoma) is the critical safety frontier to be defined before clinical translation.

Example 6: Xenotransplantation

Organ shortages killing 20 patients per day on transplant waiting lists in the US alone could be partially addressed by xenotransplantation—transplanting genetically modified pig organs into humans. Key CRISPR modifications enabling pig-to-human compatibility: knockout of 3 pig alpha-1,3-galactosyltransferase (GGTA1) glycan xenoantigens causing hyperacute rejection; insertion of human complement regulatory proteins (CD55, CD46, CD59) protecting against complement attack; insertion of human coagulation regulatory genes (TFPI, TBM, EPCR); knockout of porcine endogenous retroviruses (PERVs); and humanisation of pig MHC class II antigens reducing adaptive immune recognition. In 2022-2023, genetically modified pig hearts were transplanted into two brain-dead humans and one living patient (Richard Slayman kidney, 2024) showing function for weeks. Pig kidneys, hearts, and livers with 10-gene modifications are approaches multiple companies (eGenesis, Revivicor) are advancing to clinical trials.

Example 7: DNA Data Storage

DNA is the most compact and durable information storage medium known—potentially storing 215 petabytes of data per gram with theoretical stability for >1000 years under proper conditions. The cost of oligonucleotide synthesis and sequencing has fallen exponentially—making DNA data storage increasingly economically competitive with magnetic tape for long-term archival (cold storage). In 2016, Microsoft and University of Washington stored and retrieved 200 MB in DNA; by 2021, entire machine learning models were encoded in DNA; by 2040, DNA storage for genomic databases, medical imaging archives, and multimedia content may become commercially viable. The challenge is read/write speed and random access—sequencing remains slow and expensive relative to solid state storage, but PCR-based random access and novel enzymatic approaches are under development. DNA data storage exemplifies the convergence of biology and information technology as dual-use technologies.

Example 8: Biology and the Climate Crisis

Biology will be both a frontline tool and a victim of the climate crisis. Engineered organisms for climate mitigation: photosynthesis-enhanced crop plants fixing more CO2 per unit area through introduction of C4 pathways into C3 crops (RIPE project); enhanced rock weathering using microorganisms accelerating mineral carbonation for CO2 sequestration; bioengineered algae producing biofuel as petroleum substitutes; CRISPR-proofed coral strains tolerant to higher sea temperatures for reef restoration. Climate adaptation requires understanding of species tolerance limits, accelerating evolutionary adaptation through assisted gene flow (deliberately introducing adaptive variants from warm-adapted populations into at-risk populations), and de-extinction or genetic rescue of species threatened by climate-pace change. The intersection of synthetic biology, conservation genetics, and climate science will define much of biology's societal relevance in the coming decades—biology as an essential participant in both planetary diagnosis and planetary therapy.

Try it live

Everything above runs in your browser — open Longevity Escape Velocity Simulator and change the parameters while it is running. Nothing is installed, nothing is uploaded, the whole model lives in one tab.